Form D · Pharmaceuticals
Trillium Therapeutics Inc.
Mississauga, A6 · CIK 0001616212
Offering snapshot reported Dec 12, 2017 · SEC filing
- Reported sold
- $20M Offering amount: $20M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 1, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 12, 2017 | Initial | $19,975,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.2M
- Finders' fees
- $0
- Form D file number
- 021-300546
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cowen and Company, LLC | 7616 |
Source: Form D, filed Dec 12, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luke Beshar | Director |
| Henry Frieson | Director |
| Robert Kirkman | Director |
| Michael Moore | Director |
| James Parsons | Executive |
| Penka Petrova | Executive |
| Thomas Reynolds | Director |
| Eric Sievers | Executive |
| Niclas Stiernholm | Director, Executive |
| Calvin Stiller | Director |
| Helen Tayton Martin | Director |
| Robert Uger | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2488 Dunwin Drive
Mississauga, A6, L5L 1J9
Mississauga, A6, L5L 1J9